Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Award of the Dr A.T. Shousha Foundation Prize and Fellowship To Dr. Walid Ammar



Regional Committee for the Eastern Mediterranean                                                                    EM/RC63/INF.DOC.7 Rev.1
Sixty-third session                                                                                                                                           September 2016 
Provisional agenda item 9(a)


Award of the Dr A.T. Shousha Foundation Prize and Fellowship
 
  1. Following the recommendations of the Dr A.T. Shousha Foundation Committee at the Sixty-second Session of the World Health Organization (WHO) Regional Committee for the Eastern Mediterranean, the Executive Board awarded the Dr A.T. Shousha Foundation Prize for 2016, by decision EB138(5), to Dr Walid Ammar (Lebanon) for his significant contribution to public health in the geographical area in which Dr Shousha served WHO.
 
  1. Dr Walid Ammar is being honoured for his significant contribution to public health in Lebanon, in particular in the areas of primary health care and health policy, and for his efforts in translating research and evidence into policy, programmes and practice and his efforts to voice the interests of the Region in all WHO forums. Dr Ammar graduated from the medical college of the Université Libre de Bruxelles, Belgium, in 1982, and received a master’s degree in public health and a diplôme d’études approfondies from the Lebanese University in 1996. In 2001, he was awarded a PhD in epidemiology from the Université Victor Segalen in Bordeaux, France (Université Bordeaux II).
 
  1. Since 1993, Dr Ammar has been Director-General of the Ministry of Public Health of Lebanon, bringing together a range of stakeholders to chart a vision for the welfare, rights and health care in an open network model of governance. Among other achievements, Dr Ammar set up Lebanon’s primary health care network in 1994 and initiated the first national hospital accreditation system in the Eastern Mediterranean Region, and was instrumental in strengthening and developing the Lebanese health care system. In a time of political instability and under his leadership, reforms led to significant improvement in health indicators while decreasing the GDP share of health expenditures, mostly as a result of meaningful reduction in household out-of-pocket spending.
 
  1. Dr Ammar is a model for public health professionals, having served not only in government and in the academic community but also in numerous national, regional and international organizations, boards and councils. Dr Ammar has produced numerous publications in the areas of health systems, health reform and good governance. His work as a researcher has led to the development of major studies which have been pivotal in reforming the health care system of Lebanon. 
Attribution du Prix et de la Bourse d’études de la Fondation Dr A.T. Shousha a Dr. Walid Ammar
 
Awarding Ceremony, Cairo, October 3, 2016-Laureat address-Walid Ammar MD, Ph.D



    1
ATC Name B/G Ingredients Dosage Form ↑ Price
A10BB12 JOSWE GLEMAX 2 G Glimepiride - 2mg 2mg Caplet 139,760 L.L
A10BB12 JOSWE GLEMAX 3 G Glimepiride - 3mg 3mg Caplet 235,172 L.L
A10BB12 JOSWE GLEMAX 4 G Glimepiride - 4mg 4mg Caplet 235,172 L.L
A10BB12 JOSWE GLEMAX 6 G Glimepiride - 6mg 6mg Caplet 663,858 L.L
C10AA05 JOSWE ATORVAST 10 G Atorvastatin - 10mg 10mg Caplet, film coated 849,308 L.L
C10AA05 JOSWE ATORVAST 20 G Atorvastatin - 20mg 20mg Caplet, film coated 956,816 L.L
C10AA05 JOSWE ATORVAST 40 G Atorvastatin - 40mg 40mg Caplet, film coated 1,327,716 L.L
C10BX03 JOSWE DUBARA 5/10 G Amlodipine - 5mg, Atorvastatin - 10mg Caplet, film coated 2,370,538 L.L
C10BX03 JOSWE DUBARA 10/10 G Amlodipine - 10mg, Atorvastatin - 10mg Caplet, film coated 2,655,433 L.L
A02BC03 JOSWE LANZOTEC 30 G Lansoprazole - 30mg 30mg Capsule 271,456 L.L
A02BC03 JOSWE LANZOTEC 30 G Lansoprazole - 30mg 30mg Capsule 514,692 L.L
A02BC03 JOSWE LANZOTEC 15 G Lansoprazole - 15mg 15mg Capsule 270,112 L.L
M01AH01 JOSWE FLAMEX 200 G Celecoxib - 200mg 200mg Capsule 225,766 L.L
M01AH01 JOSWE FLAMEX 200 G Celecoxib - 200mg 200mg Capsule 636,981 L.L
M01AH01 JOSWE FLAMEX 400 G Celecoxib - 400mg 400mg Capsule 585,915 L.L
M01AH01 JOSWE FLAMEX 400 G Celecoxib - 400mg 400mg Capsule 1,400,284 L.L
D06BB10 JEDARA G Imiquimod - 5% 5% Cream 3,850,109 L.L
D11AX11 JOLITE FORTE CREAM G Hydroquinone - 4% 4g/100g Cream 612,792 L.L
L01CD04 JEVTANA INJECTION B Cabazitaxel - 60mg/1.5ml 60mg/1.5ml Injectable dry powder for solution+diluent 75,619,931 L.L
L01CD04 JEVTANA INJECTION B Cabazitaxel - 60mg/1.5ml 60mg/1.5ml Injectable dry powder for solution+diluent 75,619,931 L.L
A10AB01 JUSLINE R BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable solution 401,809 L.L
B03BA01 JECTIN-12 G Cyanocobalamin - 1000mcg/1ml 1000mcg/1ml Injectable solution 567,102 L.L
A10AD01 JUSLINE BioTech Insulin (human) - 100IU/ml 100IU/ml Injectable suspension 401,809 L.L
A10AE01 JUSLINE N BioTech Insulin human isophane - 100IU/ml 100IU/ml Injectable suspension 401,809 L.L
J01CR02 JULMENTIN 2X G Amoxicillin (trihydrate) - 400mg/5ml, Clavulanic Acid (potassium) - 57mg/5ml 457mg/5ml Powder for suspension 278,175 L.L
J01CR02 JULMENTIN ES G Amoxicillin (trihydrate) - 600mg/5ml, Clavulanic Acid (potassium) - 42.9mg/5ml 642.9mg/5ml Powder for suspension 507,972 L.L
R05CA12 JOS-PAN G Dried Ivy leaf extract (Hederacoside C) - 75mg/100ml Syrup 306,396 L.L
N05AH04 JOSWE QUZAL 25 G Quetiapine - 25mg 25mg Tablet 258,018 L.L
N05AH04 JOSWE QUZAL 25 G Quetiapine - 25mg 25mg Tablet 490,503 L.L
M03BX08 JAMP-CYCLOBENZAPRINE G Cyclobenzaprine HCl - 10mg 10mg Tablet 4,031,528 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026